Non-crystalline and crystalline rheumatic disorders in chronic kidney disease

Current Rheumatology Reports

Volumn 10, Issue 3, 2008, Pages 235-248

  Sarraf, Pasha ^b   Kay, Jonathan ^b   Reginato, Anthony M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM OXALATE; CALCIUM PHOSPHATE; CALCIUM PYROPHOSPHATE; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; GLUTAMIC ACID; HYDROXYAPATITE; HYDROXYCHLOROQUINE; INDOMETACIN; MATRIX METALLOPROTEINASE; MYOSTATIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOGENIC PROTEIN 1; OSTEOPROTEGERIN; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLACEBO; PREDNISOLONE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYROPHOSPHATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOMATOMEDIN; TRANSCRIPTION FACTOR FKHRL1; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG; URATE;

ARTHRALGIA; ARTHROPATHY; AUTOPHAGY; AVASCULAR NECROSIS; BLOOD TOXICITY; BLOOD VESSEL CALCIFICATION; BONE REMODELING; BONE TURNOVER; BURSITIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CRYSTALLINE RHEUMATIC DISEASE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GOUT; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMOBILIZATION; INFECTION; KIDNEY FIBROSIS; LOW DRUG DOSE; MUSCLE ATROPHY; MUSCLE TWITCH; NEPHROTOXICITY; NEUROTOXICITY; NON CRYSTALLINE RHEUMATIC DISEASE; NONHUMAN; PHYSIOTHERAPY; PROTEIN FUNCTION; PSEUDOGOUT; RENAL OSTEODYSTROPHY; REVIEW; RHEUMATIC DISEASE; SINGLE DRUG DOSE; SOFT TISSUE CALCIFICATION; TENDINITIS; TENDON DISEASE; TENDON RUPTURE; UREMIA; UREMIC POLYNEUROPATHY; URINARY TRACT DISEASE; CHONDROCALCINOSIS; CRYSTALLIZATION; METABOLISM; PATHOPHYSIOLOGY;

BONE REMODELING; CALCIUM OXALATE; CHONDROCALCINOSIS; CRYSTALLIZATION; GOUT; HUMANS; RENAL OSTEODYSTROPHY; RHEUMATIC DISEASES; UREMIA;

EID: 51449120290     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0038-1     Document Type: Review

References (102)

1. Brown EA, Gower PE: Joint problems in patients on maintenance hemodialysis. Clin Nephrol 1982, 18:247-250.
2. Goldstein S, Winston E, Chung TJ, et al.: Chronic arthropathy in long-term hemodialysis. Am J Med 1985, 78:82-86.
3. Todd D, Kay J: Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Cur Rheum Rep 2008 10:195-204.
4. Seeman E: Invited review: Pathogenesis of osteoporosis. J Appl Physiol 2003, 95:2142-2151.
5. Seeman E, Delmas PD: Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
6. Heaney RP: The bone remodeling transient: interpreting interventions involving bone-related nutrients. Nutr Rev 2001, 59:327-334.
7. Heaney RP: How does bone support calcium homeostasis? Bone, 2003, 33:264-268.
8. Heaney RP: Is the paradigm shifting? Bone 2003, 33:457-465.
9. Seeman E: Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 2007, 41:308-317.
10. Elder G: Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002, 17:2094-2105.
11. Miller PD: Treatment of metabolic bone disease in patients with chronic renal disease: a perspective for rheumatologists. Curr Rheumatol Rep 2005, 7:53-60.
12. Lewiecki EM, Miller PD: Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf 2007, 6:663-672.
13. Zierath JR, Hawley JA: Skeletal muscle fiber type: influence on contractile and metabolic properties. PLoS Biol 2004, 2:e348.
14. Kopple JD, Storer T, Casburi R, et al.: Impaired exercise capacity and exercise training in maintenance hemodialysis patients. J Ren Nutr 2005, 15:44-48.
15. Storer TW, Casaburi R, Sawelson S, Kopple JD: Endurance exercise training during haemodialysis improves strength, power, fatigability and physical performance in maintenance haemodialysis patients. Nephrol Dial Transplant 2005, 20:1429-1437.
16. Harrison AP, Nielsen AH, Eidemak I, et al.: The uremic environment and muscle dysfunction in man and rat. Nephron Physiol 2006, 103:33-42.
17. Campistol JM: Uremic myopathy. Kidney Int 2002, 62:1901-1913.
18. Handschin C, Spiegelman BM: Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 2006, 27:728-735.
19. Lecker SH, Jagoe RT, Gilbert A, et al.: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004, 18:39-51.
20. Jagoe RT, Lecker SH, Gomes M, Goldberg AL: Patterns of gene expression in atrophying skeletal muscles: response to food deprivation. FASEB J 2002, 16:1697-1712.
21. Sandri M, Sandri C, Gilbert A, et al.: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
22. Hanai J, Cao P, Tanksale P, et al.: The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007, 117:3940-3951.
23. Levine S, Nguyen T, Taylor N, et al.: Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med 2008, 358:1327-1335.
24. Mammucari C, Milan G, Romanello V, et al.: FoxO3 controls autophagy in skeletal muscle in vivo. Cell Met 2007, 6:458-471.
25. Raben N, Roberts A, Plotz PH: Role of autophagy in the pathogenesis of Pompe disease. Acta Myol 2007, 26:45-48.
26. Sandri M, Lin J, Handschin C, et al.: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A 2006, 103:16260-16265.
27. Bruusgaard JC, Gundersen K: In vivo time-lapse microscopy reveals no loss of murine myonuclei during weeks of muscle atrophy. J Clin Invest 2008, 118:1450-1457.
28. Lee SJ: Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 2004, 20:61-86.
29. Gilson H, Schakman O, Combaret L, et al.: Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 2007, 148:452-460.
30. Sun DF, Chen Y, Rabkin R: Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia. Kidney Int 2006, 70:453-459.
31. Mak RH, Rotwein P: Myostatin and insulin-like growth factors in uremic sarcopenia: the yin and yang in muscle mass regulation. Kidney Int 2006, 70:410-412.
32. Zimmers TA, Davies MV, Koniaris LG, et al.: Induction of cachexia in mice by systemically administered myostatin. Science 2002, 296:1486-1488.
33. Glerup H, Mikkelsen K, Poulsen L, et al.: Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int 2000, 66:419-424.
34. Krishnan AV, Kiernan MC: Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 2007, 35:273-290.
35. Baczynski R, Massry SG, Magott M, et al.: Effect of parathyroid hormone on energy metabolism of skeletal muscle. Kidney Int 1985, 28:722-727.
36. Riley G: Tendinopathy - from basic science to treatment. Nat Clin Pract Rheumatol 2008, 4:82-89.
37. Drummond AH, Beckett P, Brown PD, et al.: Preclinical and clinical studies of inhibitors in cancer. Ann N Y Acad Sci 1999, 878:228-235.
38. Corps AN, Harrall RL, Curry VA, et al.: Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1beta in human tendon-derived cells. A potential mechanism of fluoroquinolone-induced tendinopathy. Arthritis Rheum 2002, 46:3034-3040.
39. Pasternak B, Fellenius M, Aspenberg P: Doxycycline impairs tendon repair in rats. Acta Orthop Belg 2006, 72:756-760.
40. Mendias CL, Bakhurin KI, Faulkner JA: Tendons of myostatin-deficient mice are small, brittle, and hypocellular. Proc Natl Acad Sci U S A 2008, 105:388-393.
41. Shah MK: Simultaneous bilateral quadriceps tendon rupture in renal patients. Clin Nephrol 2002, 58:118-121.
42. Khaliq Y, Zhanel GG: Musculoskeletal injury associated with fluoroquinolone antibiotics. Clin Plast Surg 2005, 32:495-502.
43. London GM, Marchais SJ, Guérin AP, Métivier F: Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005, 14:525-531.
44. Moss DW, Eaton RH, Smith JK, Whitby LG: Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations. Biochem J 1967, 102:53-57.
45. Terkeltaub R, Rosenbach M, Fong F, Goding J: Causal link between nucleotide pyrophosphohydrolase overactivity and increased intracellular inorganic pyrophosphate generation demonstrated by transfection of cultured fibroblasts and osteoblasts with plasma cell membrane glycoprotein-1. Relevance to calcium pyrophosphate dihydrate deposition disease. Arthritis Rheum 1994, 37:934-941.
46. Ho AM, Johnson MD, Kingsley DM: Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000, 289:265-270.
47. Rutsch F, Ruf N, Vaingankar S, et al.: Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003, 34:379-381.
48. Eller P, Hochegger K, Feuchtner GM, et al.: Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. Nephrol Dial Transplant 2008, 23:321-327.
49. Mazhar AR, Johnson RJ, Gillen D, et al.: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001, 60:324-332.
50. Lomashvili KA, Khawandi W, O'Neill WC: Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005, 16:2495-2500.
51. Zebboudj AF, Imura M, Boström K: Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002, 277:4388-4394.
52. Chen NX, Duan D, O'Neill KD, et al.: The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int 2006, 70:1046-1053.
53. Luo G, Ducy P, McKee MD, et al.: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997, 386:78-81.
54. Murshed M, Schinke T, McKee MD, Karsenty G: Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004, 165:625-630.
55. Nishimoto SK, Price PA. The vitamin K-dependent bone protein is accumulated within cultured osteosarcoma cells in the presence of the vitamin K antagonist warfarin. J Biol Chem 1985, 260:2832-2836.
56. Brancaccio D, Biondi ML, Gallieni M, et al.: Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol 2005, 25:548-552.
57. Schafer C, Heiss A, Schwarz A, et al.: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003, 112:357-366.
58. Reynolds JL, Skepper JN, McNair R, et al.: Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005, 16:2920-2930.
59. Ketteler M, Bongartz P, Westenfeld R, et al.: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003, 361:827-833.
60. Cozzolino M, Galassi A, Biondi ML, et al.: Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol 2006, 26:423-429.
61. Proudfoot D, Skepper JN, Hegyi L, et al.: Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000, 87:1055-1062.
62. Reynolds JL, Joannides AJ, Skepper JN, et al.: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004, 15:2857-2867.
63. Tyson KL, Reynolds JL, McNair R, et al.: Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003, 23:489-494.
64. Dorai H, Vukicevic S, Sampath TK: Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 2000, 184:37-45.
65. Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, et al.: sRANKL/ osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients. J Endocrinol Invest 2007, 30:762-766.
66. Imanishi Y, Inaba M, Nakatsuka K, et al.: FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004, 65:1943-1946.
67. Westerberg PA, Linde T, Wikström B, et al.: Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007, 22:3202-3207.
68. Benet-Pagès A, Orlik P, Strom TM, Lorenz-Depiereux B: An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005, 14:385-390.
69. Urakawa I, Yamazaki Y, Shimada T, et al.: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
70. Stubbs J, Liu S, Quarles LD: Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007, 20:302-308.
71. Church LD, Cook GP, McDermott MF: Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 2008, 4:34-42.
72. Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R: TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol 2005, 174:5016-5023.
73. Liu-Bryan R, Scott P, Sydlaske A, et al.: Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936-2946.
74. Martinon F, Pétrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
75. Chen CJ, Shi Y, Hearn A, et al.: MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006, 116:2262-2271.
76. McGonagle D, Tan AL, Shankaranarayana S, et al.: Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007, 66:1683-1684.
77. McGonagle D, Tan AL, Madden J, et al.: Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008, 58:631-633.
78. Schreiner O, Wandel E, Himmelsbach F, et al.: Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients? Nephrol Dial Transplant 2000, 15:644-649.
79. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM: Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int 2008, 73:384-390.
80. Ellman MH, Brown NL, Katzenberg CA: Acute pseudogout in chronic renal failure. Arch Intern Med 1979, 139:795-796.
81. Menerey K, Braunstein E, Brown M, et al.: Musculoskeletal symptoms related to arthropathy in patients receiving dialysis. J Rheumatol 1988, 15:1848-1854.
82. Johnson K, Terkeltaub R: Upregulated ank expression in osteoarthritis can promote both chondrocyte MMP-13 expression and calcification via chondrocyte extracellular PPi excess. Osteoarthritis Cartilage 2004, 12:321-335.
83. Kuntz D, Naveau B, Bardin T, et al.: Destructive spondylarthropathy in hemodialyzed patients. A new syndrome. Arthritis Rheum 1984, 27:369-375.
84. Kart-Köseoglu H, Yucel AE, Niron EA, et al.: Osteoarthritis in hemodialysis patients: relationships with bone mineral density and other clinical and laboratory parameters. Rheumatol Int 2005, 25:270-275.
85. Braunstein EM, Menerey K, Martel W, et al.: Radiologic features of a pyrophosphate-like arthropathy associated with long-term dialysis. Skeletal Radiol 1987, 16:437-441.
86. Ferrari AJ, Rothfuss S, Schumacher HR Jr: Dialysis arthropathy: identification and evaluation of a subset of patients with unexplained inflammatory effusions. J Rheumatol 1997, 24:1780-1786.
87. Hoffman GS, Schumacher HR, Paul H, et al.: Calcium oxalate microcrystalline-associated arthritis in end-stage renal disease. Ann Intern Med 1982, 97:36-42.
88. Reginato AJ, Ferreiro Seoane JL, Barbazan Alvarez C, et al.: Arthropathy and cutaneous calcinosis in hemodialysis oxalosis. Arthritis Rheum 1986, 29:1387-1396.
89. Abuelo JG, Schwartz ST, Reginato AJ: Cutaneous oxalosis after long-term hemodialysis. Arch Intern Med 1992, 152:1517-1520.
90. Reginato AJ, Kurnik B: Calcium oxalate and other crystals associated with kidney diseases and arthritis. Semin Arthritis Rheum 1989, 18:198-224.
91. Newcombe DS: Endocrinopathies and uric acid metabolism. Semin Arthritis Rheum 1972, 2:281-300.
92. Buchanan WW, Klinenberg JR, Seegmiller JE: The inflammatory response to injected microcrystalline monosodium urate in normal, hyperuricemic, gouty, and uremic subjects. Arthritis Rheum 1965, 8:361-367.
93. Sombolos K, Tsitamidou Z, Kyriazis G, et al.: Clinical evaluation of four different high-flux hemodialyzers under conventional conditions in vivo. Am J Nephrol 1997, 17:406-412.
94. Mathews M, Shen FH, Lindner A, Sherrard DJ: Septic arthritis in hemodialyzed patients. Nephron 1980, 25:87-91.
95. Kaslow RA, Zellner SR: Infection in patients on maintenance haemodialysis. Lancet 1972, 2:117-119.
96. Kurella M, Bennett WM, Chertow GM: Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 2003, 42:217-228.
97. Neil E, Scherrmann JM: Colchicine today. Joint Bone Spine 2006, 73:672-678.
98. Zhang W, Doherty M, Pascual E, et al.; EULAR Standing Committee for International Clinical Studies Including Therapeutics: EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1301-1311.
99. Zhang W, Doherty M, Bardin T, et al.; EULAR Standing Committee for International Clinical Studies Including Therapeutics: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
100. Man CY, Cheung IT, Cameron PA, Rainer TH: Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007, 49:670-677.
101. Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47-56.
102. Rothschild B, Yakubov LE: Prospective 6-month, doubleblind trial of hydroxychloroquine treatment of CPDD. Compr Ther 1997, 23:327-331.